A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

New Scalable Options for Panther System Launches in the US and Europe

Hologic Reports Panther Scalable Solutions Are Commercially Available in These Markets

The Panther Scalable Solutions (PSS) portfolio are now commercially available in the United States and Europe, reports Hologic today. These new optional configurations, which represent Hologic’s next generation of molecular diagnostics innovation, will allow laboratories to scale their instrumentation to meet testing demands in both their current workflow and their future growth plans.

“Our laboratory partners seek continuing efficiency and consolidation, and we are observing that trend in real-time, with more Panther instruments in the field running multiple assays than ever before”

“Our laboratory partners seek continuing efficiency and consolidation, and we are observing that trend in real-time, with more Panther instruments in the field running multiple assays than ever before,” said Kevin Thornal, president, Diagnostic Solutions Division at Hologic. “In the tenth year since launching the Panther system, we are excited to add expanded capabilities to our market-leading molecular diagnostic platform.”

The Panther system, launched in Europe in 2010, offers random access and full automation for molecular testing. It provides a broad assay menu that includes tests for women’s health, sexually transmitted infections (STIs), respiratory health, and viral load, as well as Open Access functionality for laboratory-developed tests (LDTs). This broad menu enables labs to consolidate molecular testing onto a single platform.

Within Panther Scalable Solutions, the Panther system functions as the foundation for optional add-ons. These add-ons include Panther Fusion, which launched in 2016 and provides additional IVD menu and the Open Access functionality, the now available Panther Plus and Panther Link, as well as the upcoming Panther Trax.

Taken together, these configurable options address the needs of today’s laboratories, allowing them to increase operational capacity and testing volumes at their own pace while building on the flexibility and streamlined user experience they require. Panther Scalable Solutions allows laboratories to choose custom configurations that best suit their needs and testing volumes as they evolve over time. These new options expand upon the proven performance and reliability of the Panther system.

The new optional configurations include:

  • Panther Plus, which adds flexibility, capacity and throughput to the existing Panther system. With Panther Plus, labs can load more consumables directly on the instrument, allowing even greater walkaway time (up to 13.5 consecutive hours). Both fluids and waste can be changed while tests are in process, and an option for automatic liquid waste disposal is available. These features allow an additional 210 tests to be run in 24 hours, providing a total throughput of greater than 1,200 patient samples in that time. Panther Plus is FDA-approved and CE-Marked and is now available in the United States and Europe.
  • Panther Link is a software solution that provides additional efficiencies by creating a virtual connection that allows multiple Panther instruments to communicate with one another and function within a singular, streamlined workflow. Linked instruments can share information such as reagent kits and reflex test orders, enabling more efficient reagent utilization and improved turnaround time. A dashboard command feature allows technicians to monitor instrument inventories, maintenance tasks and test results on a single screen from a centralized location. Panther Link is FDA-approved and CE-Marked and is now available in the United States and Europe.

In addition, Hologic is developing Panther Trax, which will offer the ultimate in lab automation by physically and electronically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff. Panther Trax is expected to be available in the United States and Europe later in 2020.

SourceHologic
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy